You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物高開2.15% 達伯舒®(信迪利單抗注射液)一季度銷售4億元
格隆匯 04-24 09:32
格隆匯4月24日丨信達生物-B(1801.HK)高開2.15%,報35.6港元,暫成交1701萬港元,最新總市值477億港元。信達生物昨晚公佈,達伯舒®(信迪利單抗注射液)是由與集團禮來製藥共同開發的,並於2019年3月成功推出,於2020年第一季度,有關銷售收入約為人民幣4億元。公司相信業績反映其主要藥物產品達伯舒®的潛力。此外,公司今日早間公佈,集團和禮來製藥共同開發的創新PD-1抑制劑達伯舒(信迪利單抗注射液)聯合力比泰(注射用培美曲塞二鈉)和鉑類用於非鱗狀非小細胞肺癌一線治療的新適應症申請(sNDA)已經正式獲中國國家藥品監督管理局(NMPA)受理。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account